Caplin Point Laboratories Limited (NSE:CAPLIPOINT)
India · Delayed Price · Currency is INR | Market Cap | 199.30B +24.4% |
| Revenue (ttm) | 21.87B +12.8% |
| Net Income | 6.41B +19.6% |
| EPS | 84.11 +19.7% |
| Shares Out | n/a |
| PE Ratio | 31.08 |
| Forward PE | 27.96 |
| Dividend | 7.00 (0.27%) |
| Ex-Dividend Date | May 29, 2026 |
| Volume | 93,945 |
| Open | 2,629.70 |
| Previous Close | 2,623.80 |
| Day's Range | 2,604.60 - 2,659.90 |
| 52-Week Range | 1,500.30 - 2,699.00 |
| Beta | 0.37 |
| Analysts | Strong Buy |
| Price Target | 2,505.00 (-5.08%) |
| Earnings Date | Aug 12, 2026 |
About Caplin Point Laboratories
Caplin Point Laboratories Limited, together with its subsidiaries, engages in the development, production, marketing, and export of generic formulations and branded products in India. The company provides tablets, capsules, injections, ophthalmic, liquid orals, softgel capsules, ointments, creams and gels, powder for injections, suppositories, ovules, pre-mix bag formulations, inhalers, and sprays and IV infusion. It also provides dry and syrups, lyophilized vials, prefilled syringes, emulsion injection, sachets, liquid injectables, topicals, p... [Read more]
Financial Performance
In fiscal year 2026, Caplin Point Laboratories's revenue was 21.87 billion, an increase of 12.77% compared to the previous year's 19.40 billion. Earnings were 6.41 billion, an increase of 19.57%.
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for CAPLIPOINT stock is "Strong Buy." The 12-month stock price target is ₹2,505, which is a decrease of -5.08% from the latest price.
News
Top gainers in morning trade: balaji amines at ₹2,237.30 up 7.00%, ola electric mobility at ₹47.51 up 6.93%, caplin point laboratories at ₹2,216.00 up 4.97%
The Indian stock market displayed a steady performance this morning, with the Sensex inching up by 0.03% to 73,545.09 and the Nifty 50 rising by 0.09% to 23,144.80. Among the…
Caplin Point Laboratories Transcript: Q4 25/26
Revenue and profits saw robust multi-year growth, with strong cash reserves and zero debt. Expansion in injectables, U.S. and LATAM markets, and disciplined CapEx position the business for sustained double-digit growth and high margins in coming years.
Caplin Point Laboratories Slides: Q4 2026
Caplin Point Laboratories has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on May 14, 2026.
Caplin Point Laboratories Quarterly report: Q4 2026
Caplin Point Laboratories has published its Q4 2026 quarterly earnings report on May 14, 2026.
Caplin Point subsidiary receives USFDA approval for Calcium Gluconate Injection; targets $71 million US market
Caplin Steriles Limited (CSL), the wholly owned subsidiary of Caplin Point Laboratories Limited, has secured final approval from the United States Food and Drug Administration (USFDA) for its Abbrevia...
Caplin Point receives USFDA approval for potassium phosphates injection
Caplin Steriles Limited, a subsidiary of Caplin Point Laboratories, has secured final approval from the USFDA for its potassium phosphates injection. The product is a generic equivalent of Fresenius K...
Caplin Point Laboratories arm receives USFDA approval for potassium phosphates injection
Caplin Point Laboratories announced that its subsidiary Caplin Steriles Limited has received final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug App...
Caplin Point subsidiary secures USFDA final approval for Desmopressin Acetate Injection ANDA
Caplin Steriles Limited, a subsidiary of Caplin Point Laboratories Limited (BSE: 524742 | NSE: CAPLIPOINT), has secured final approval from...
Caplin Point subsidiary secures USFDA approval for Sodium Phosphates Injection
Caplin Steriles Limited, a wholly owned subsidiary of Caplin Point Laboratories Limited (BSE: 524742 | NSE: CAPLIPOINT), has secured final...
Caplin Point Laboratories Transcript: Q3 25/26
Q3 FY26 saw double-digit revenue and profit growth, margin expansion, and strong cash flow. US and Latin America drive future growth, with new product launches, regulatory approvals, and major CapEx investments supporting long-term expansion.
Caplin Point Laboratories Quarterly report: Q3 2026
Caplin Point Laboratories has published its Q3 2026 quarterly earnings report on February 5, 2026.
Caplin Point Laboratories Slides: Q3 2026
Caplin Point Laboratories has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on February 5, 2026.
Caplin Point subsidiary receives USFDA approval for Methylprednisolone Acetate Injectable
Caplin Steriles Limited, a subsidiary of Caplin Point Laboratories Limited, has received final approval from the United States Food and...
Caplin Point Laboratories subsidiary secures USFDA approval for Generic Linezolid Injection
Caplin Steriles Limited, the subsidiary of Caplin Point Laboratories, has received final approval from the US Food and Drug Administration...
Caplin Point Laboratories subsidiary receives USFDA approval for Acetaminophen Injection ANDA
Caplin Steriles Limited, the sterile injectables subsidiary of Caplin Point Laboratories Limited, has secured final approval from the United States...
Caplin Point Laboratories Transcript: Q2 25/26
Revenue and profit margins grew strongly in H1 FY26, with PAT up 21.6% and EBITDA margin expanding. Expansion in the U.S., Mexico, and Latin America, along with robust cash reserves, positions the company for continued growth and potential acquisitions.
Caplin Point Laboratories Quarterly report: Q2 2026
Caplin Point Laboratories has published its Q2 2026 quarterly earnings report on November 6, 2025.
Caplin Point Laboratories Slides: Q2 2026
Caplin Point Laboratories has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on November 6, 2025.
Caplin Point subsidiary gets USFDA nod for Milrinone Lactate in 5% Dextrose Injection
Caplin Steriles Limited, a subsidiary of Caplin Point Laboratories Limited (BSE: 524742, NSE: CAPLIPOINT), has received final approval from the US Food and Drug Administration (USFDA) for its Abbrevia...
Caplin Point Laboratories Transcript: Q1 25/26
Q1 FY2026 delivered 11.7% revenue growth and 20.7% PAT growth, driven by strong Latin America and U.S. performance, robust margins, and a focus on asset-light models. Management projects continued double-digit growth, with new product launches and CapEx supporting future expansion.
Caplin Point Laboratories Quarterly report: Q1 2026
Caplin Point Laboratories has published its Q1 2026 quarterly earnings report on August 7, 2025.
Caplin Point Laboratories Slides: Q1 2026
Caplin Point Laboratories has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on August 7, 2025.
Caplin Point shares surge 5% as Q1 revenue jumps 11% YoY to Rs 510 crore, net profit up 23.2% YoY
Caplin Point Laboratories witnessed a strong rally in its stock price on Thursday, surging over 5% after the company posted robust Q1 FY26 results. The stock opened at ₹1,900 and climbed as high as ₹2...
Caplin Point subsidiary to acquire Mexican pharma firm Triwin Pharma S.A. DE C.V.
Caplin Point Laboratories, through its wholly owned subsidiary Caplin Point Far East Limited based in Hong Kong, has entered into a Share Purchase Agreement dated June 3, 2025, to acquire the entire s...
Caplin Point Laboratories Transcript: Q4 24/25
Revenue grew 15% to INR 2,034 crore and PAT rose 17% to INR 541 crore, with record margins and strong liquidity. Caplin Steriles posted INR 366 crore revenue and INR 102 crore EBITDA. Management expects a transition period of 18–24 months before new growth drivers fully materialize.